CLINICAL TRIALS PROFILE FOR POTIGA

All Clinical Trials for POTIGA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02149836 ↗	Study to Treat Major Depressive Disorder (MDD) With a New Medication	Completed	Icahn School of Medicine at Mount Sinai	Phase 2	2014-08-01	The purpose of this study is to test the antidepressant effects of Ezogabine in major depressive disorder (MDD). The investigators also aim to determine the safety and tolerability Ezogabine in patients with MDD. The investigators hypothesize that depressive symptoms will be significantly decreased following an 8-week treatment period of the medication compared to baseline.
NCT02450552 ↗	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects	Completed	ALS Association	Phase 2	2015-06-01	This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 ↗	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects	Completed	GlaxoSmithKline	Phase 2	2015-06-01	This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 ↗	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects	Completed	Harvard University	Phase 2	2015-06-01	This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 ↗	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects	Completed	Massachusetts General Hospital	Phase 2	2015-06-01	This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT02450552 ↗	Clinical Trial of Ezogabine (Retigabine) in ALS Subjects	Completed	Brian Wainger	Phase 2	2015-06-01	This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
NCT03043560 ↗	Study to Treat Major Depressive Disorder With a New Medication	Completed	Baylor College of Medicine	Phase 2	2017-09-25	This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga, GlaxoSmithKline; FDA-approved for the treatment of seizure disorders).

Clinical Trial Conditions for POTIGA

Condition Name

Condition Name for POTIGA
Intervention	Trials
Amyotrophic Lateral Sclerosis	1
Anhedonia	1
Depression	1
Depressive Disorder	1

Condition MeSH

Condition MeSH for POTIGA
Intervention	Trials
Disease	2
Depressive Disorder	2
Depression	2
Amyotrophic Lateral Sclerosis	1

Clinical Trial Locations for POTIGA

Trials by Country

Trials by Country for POTIGA
Location	Trials
United States	13

Trials by US State

Trials by US State for POTIGA
Location	Trials
New York	3
Texas	1
Pennsylvania	1
North Carolina	1
Michigan	1

Clinical Trial Progress for POTIGA

Clinical Trial Phase

Clinical Trial Phase for POTIGA
Clinical Trial Phase	Trials
Phase 2	3

Clinical Trial Status

Clinical Trial Status for POTIGA
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for POTIGA

Sponsor Name

Sponsor Name for POTIGA
Sponsor	Trials
Harvard University	1
Massachusetts General Hospital	1
Brian Wainger	1

Sponsor Type

Sponsor Type for POTIGA
Sponsor	Trials
Other	7
NIH	1
Industry	1